A Test of Y90 Glass Beads for Brain Cancer That Came Back
Official title: An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests tiny glass beads that carry radiation right into a brain tumor.
Read our full plain-language summary
What the trial team says
The purpose of this study is to test Y90 glass microspheres for people with recurrent brain cancer. Participation in this study will help researchers find the best dose for the treatment of the disease. The study will look at the safety of the Y90 glass microsphere device and if it works to help stop the growth of the tumor. In this study, the device is delivered directly to the tumor through the blood vessels/arteries using a catheter(s) (a specialized tubing). The device (very small glass beads) gives radiation directly to the tumor and nearby area. Although radiation is a standard treatment for most types of brain cancer, the delivery of radiation using the Y90 glass microsphere device differs and is an investigational procedure. To deliver the device a catheter(s) will be inserted through a blood vessel/artery in the forearm or groin, followed by an in-hospital stay after the treatment of up-to 36 hours. Participants will have regular follow-up visits with the study doctor to monitor their health and assess how the tumor responds to treatment. These visits will take place weekly during the first month, monthly for the next five months, and then approximately every two months until one year after treatment.
Key facts
- Registry number
- NCT07867886
- Stage of testing
- Not applicable
- Conditions studied
- Recurrent Glioblastoma
Where it is running
This trial lists 5 sites.
-
France
- Hospices Civils de Lyon - Hopital Louis Pradel (Bron)
- Hôpital de La Timone (Marseille)
-
Germany
- Universitätsklinikum Tübingen (Tübingen)
-
Netherlands
- University Medical Center Utrecht (Utrecht)
-
Spain
- Vall d'Hebron Institute of Oncology (Barcelona)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.